Overview

  • Product nameUBP310
  • Description
    GluK1 and GluK3 selective antagonist
  • Biological descriptionGluK1 (formerly GluR5) and GluK3 (formerly GluR7) receptor selective antagonist (Kb =10 nM and IC50 = 23 nM, respectively). IC50 values are >100 μM at recombinant human GLUA2 (formerly GluR2), GluK2 (formerly GluR6,) GluK2/GluK5 (formerly GluR6/KA2) and GluK2/GluK3 (formerly GluR6/GluR7). Selective over native AMPA receptors (Kd = 83 μM) and exhibits no activity at NMDA and Group I mGlu receptors at concentrations of up to 10 µM.
  • Purity> 98%

Properties

    References for UBP310 (ab120168)

    This product has been referenced in:
    • Perrais D  et al. Antagonism of recombinant and native GluK3-containing kainate receptors. Neuropharmacology 56:131-40 (2009). Read more (PubMed: 18761361) »
    • Dolman NP  et al. Synthesis and pharmacological characterization of N3-substituted willardiine derivatives: role of the substituent at the 5-position of the uracil ring in the development of highly potent and selective GLUK5 kainate receptor antagonists. J Med Chem 50:1558-70 (2007). Read more (PubMed: 17348638) »
    • Mayer ML  et al. Crystal structures of the kainate receptor GluR5 ligand binding core dimer with novel GluR5-selective antagonists. J Neurosci 26:2852-61 (2006). Read more (PubMed: 16540562) »

    See all 3 Publications for this product

    Product Wall

    There are currently no Abreviews or Questions for ab120168.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE, NOT FOR USE IN HUMANS"